68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Status:
Completed
Trial end date:
2019-09-13
Target enrollment:
Participant gender:
Summary
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and
tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150
MBq and not more than 250 MBq, of 68^Ga-PSMA-R2 in adult male patients with biochemical
relapse (BR) and metastatic prostate cancer (mPCa).